| Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase … F Ciceri, C Bonini, MTL Stanghellini, A Bondanza, C Traversari, ... The lancet oncology 10 (5), 489-500, 2009 | 566 | 2009 |
| G-CSF–primed hematopoietic stem cells or G-CSF per se accelerate recovery and improve survival after liver injury, predominantly by promoting endogenous repair programs E Yannaki, E Athanasiou, A Xagorari, V Constantinou, I Batsis, ... Experimental hematology 33 (1), 108-119, 2005 | 353 | 2005 |
| A chromatin insulator protects retrovirus vectors from chromosomal position effects DW Emery, E Yannaki, J Tubb, G Stamatoyannopoulos Proceedings of the National Academy of Sciences 97 (16), 9150-9155, 2000 | 331 | 2000 |
| Development of virus vectors for gene therapy of β chain hemoglobinopathies: flanking with a chromatin insulator reduces γ-globin gene silencing in vivo DW Emery, E Yannaki, J Tubb, T Nishino, Q Li, G Stamatoyannopoulos Blood, The Journal of the American Society of Hematology 100 (6), 2012-2019, 2002 | 155 | 2002 |
| Lasting amelioration in the clinical course of decompensated alcoholic cirrhosis with boost infusions of mobilized peripheral blood stem cells E Yannaki, A Anagnostopoulos, D Kapetanos, A Xagorari, F Iordanidis, ... Experimental hematology 34 (11), 1583-1587, 2006 | 148 | 2006 |
| Mesenchymal stem cells are conditionally therapeutic in preclinical models of rheumatoid arthritis A Papadopoulou, M Yiangou, E Athanasiou, N Zogas, P Kaloyannidis, ... Annals of the rheumatic diseases 71 (10), 1733-1740, 2012 | 147 | 2012 |
| Disruption of the BCL11A erythroid enhancer reactivates fetal hemoglobin in erythroid cells of patients with β-thalassemia major N Psatha, A Reik, S Phelps, Y Zhou, D Dalas, E Yannaki, DN Levasseur, ... Molecular Therapy Methods & Clinical Development 10, 313-326, 2018 | 121 | 2018 |
| Maritime route of colonization of Europe P Paschou, P Drineas, E Yannaki, A Razou, K Kanaki, F Tsetsos, ... Proceedings of the National Academy of Sciences 111 (25), 9211-9216, 2014 | 107 | 2014 |
| Topological constraints governing the use of the chicken HS4 chromatin insulator in oncoretrovirus vectors E Yannaki, J Tubb, M Aker, G Stamatoyannopoulos, DW Emery Molecular Therapy 5 (5), 589-598, 2002 | 91 | 2002 |
| In vivo HSC prime editing rescues sickle cell disease in a mouse model C Li, A Georgakopoulou, GA Newby, PJ Chen, KA Everette, K Paschoudi, ... Blood, The Journal of the American Society of Hematology 141 (17), 2085-2099, 2023 | 89 | 2023 |
| Stem cell-based regenerative opportunities for the liver: State of the art and beyond E Tsolaki, E Yannaki World journal of gastroenterology 21 (43), 12334, 2015 | 83 | 2015 |
| Hematopoietic stem cell mobilization for gene therapy of adult patients with severe β-thalassemia: results of clinical trials using G-CSF or plerixafor in splenectomized and … E Yannaki, T Papayannopoulou, E Jonlin, F Zervou, G Karponi, ... Molecular Therapy 20 (1), 230-238, 2012 | 73 | 2012 |
| In vivo HSPC gene therapy with base editors allows for efficient reactivation of fetal γ-globin in β-YAC mice C Li, A Georgakopoulou, A Mishra, S Gil, RD Hawkins, E Yannaki, ... Blood advances 5 (4), 1122-1135, 2021 | 70 | 2021 |
| The proteasome inhibitor bortezomib drastically affects inflammation and bone disease in adjuvant‐induced arthritis in rats E Yannaki, A Papadopoulou, E Athanasiou, P Kaloyannidis, A Paraskeva, ... Arthritis & Rheumatism 62 (11), 3277-3288, 2010 | 70 | 2010 |
| In vivo HSC gene therapy using a bi-modular HDAd5/35++ vector cures sickle cell disease in a mouse model C Li, H Wang, A Georgakopoulou, S Gil, E Yannaki, A Lieber Molecular Therapy 29 (2), 822-837, 2021 | 69 | 2021 |
| Transplant‐associated thrombotic microangiopathy: incidence, prognostic factors, morbidity, and mortality in allogeneic hematopoietic cell transplantation E Gavriilaki, I Sakellari, I Batsis, D Mallouri, Z Bousiou, A Vardi, E Yannaki, ... Clinical Transplantation 32 (9), e13371, 2018 | 68 | 2018 |
| Hematopoietic stem cells and liver regeneration: differentially acting hematopoietic stem cell mobilization agents reverse induced chronic liver injury E Tsolaki, E Athanasiou, E Gounari, N Zogas, E Siotou, M Yiangou, ... Blood Cells, Molecules, and Diseases 53 (3), 124-132, 2014 | 65 | 2014 |
| Plerixafor+G-CSF–mobilized CD34+ cells represent an optimal graft source for thalassemia gene therapy G Karponi, N Psatha, CW Lederer, JE Adair, F Zervou, N Zogas, ... Blood, The Journal of the American Society of Hematology 126 (5), 616-619, 2015 | 61 | 2015 |
| Hematopoietic stem cell mobilization for gene therapy: superior mobilization by the combination of granulocyte–colony stimulating factor plus plerixafor in patients with β … E Yannaki, G Karponi, F Zervou, V Constantinou, A Bouinta, ... Human gene therapy 24 (10), 852-860, 2013 | 57 | 2013 |
| In vivo hematopoietic stem cell gene therapy ameliorates murine thalassemia intermedia H Wang, A Georgakopoulou, N Psatha, C Li, C Capsali, HB Samal, ... The Journal of clinical investigation 129 (2), 598-615, 2019 | 56 | 2019 |
Anastasia PapadopoulouGene and Cell Therapy Center - Hematology Dpt - George Papanikolaou Hospital Thessalonikiبريد إلكتروني تم التحقق منه على n3.syzefxis.gov.gr
